Dynamic changes in positive interferon-gamma release assay in a dialysis population: An observational cohort study

Journal of Infection

Volumn 67, Issue 6, 2013, Pages 529-535

  Shu, Chin Chung ^a,b   Wu, Vin Cent ^a   Yang, Feng Jung ^a   Hsu, Chia Lin ^a   Pan, Sung Ching ^a   Wang, Jann Yuan ^a   Wang, Jann Tay ^a   Yu, Chong Jen ^a   Lee, Li Na ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Conversion; Dialysis; Interferon gamma release assay; Latent tuberculosis infection; Reversion

Indexed keywords

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY;

CONVERSION; DIALYSIS; INTERFERON-GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS INFECTION; REVERSION;

AGED; FEMALE; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 84887016600     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2013.07.029     Document Type: Article

References (35)

1. Global tuberculosis report 2012 2012, World Health Organization, Geneva, Switzerland.
2. Rose D.N. Benefits of screening for latent Mycobacterium tuberculosis infection. Arch Intern Med 2000, 160:1513-1521.
3. Yang W.C., Hwang S.J. Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance. Nephrol Dial Transplant 2008, 23:3977-3982.
4. Christopoulos A.I., Diamantopoulos A.A., Dimopoulos P.A., Gumenos D.S., Barbalias G.A. Risk of tuberculosis in dialysis patients: association of tuberculin and 2,4-dinitrochlorobenzene reactivity with risk of tuberculosis. Int Urol Nephrol 2006, 38:745-751.
5. Li S.Y., Chen T.J., Chung K.W., Tsai L.W., Yang W.C., Chen J.Y., et al. Mycobacterium tuberculosis infection of end-stage renal disease patients in Taiwan: a nationwide longitudinal study. Clin Microbiol Infect 2011, 17:1646-1652.
6. Lane C., Ashcroft A., Bothamley G., Yaqoob M.M., Fan S.L. Accelerated decline of GFR in diabetic nephropathy predicted by interferon release assay to tuberculosis antigens. Nephron Clin Pract 2011, 117:c266-c269.
7. Triverio P.A., Bridevaux P.O., Roux-Lombard P., Niksic L., Rochat T., Martin P.Y., et al. Interferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients. Nephrol Dial Transplant 2009, 24:1952-1956.
8. Lee S.S., Chou K.J., Su I.J., Chen Y.S., Fang H.C., Huang T.S., et al. High prevalence of latent tuberculosis infection in patients in end-stage renal disease on hemodialysis: comparison of QuantiFERON-TB GOLD, ELISPOT, and tuberculin skin test. Infection 2009, 37:96-102.
9. Lee S.S., Chou K.J., Dou H.Y., Huang T.S., Ni Y.Y., Fang H.C., et al. High prevalence of latent tuberculosis infection in dialysis patients using the interferon-gamma release assay and tuberculin skin test. Clin J Am Soc Nephrol 2010, 5:1451-1457.
10. Shu C.C., Wu V.C., Yang F.J., Pan S.C., Lai T.S., Wang J.Y., et al. Predictors and prevalence of latent tuberculosis infection in patients receiving long-term hemodialysis and peritoneal dialysis. PLoS One 2012, 7:e42592.
11. Simsek H., Alpar S., Ucar N., Aksu F., Ceyhan I., Gozalan A., et al. Comparison of tuberculin skin testing and T-SPOT.TB for diagnosis of latent and active tuberculosis. Jpn J Infect Dis 2010, 63:99-102.
12. Brock I., Weldingh K., Lillebaek T., Follmann F., Andersen P. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004, 170:65-69.
13. Diel R., Loddenkemper R., Meywald-Walter K., Niemann S., Nienhaus A. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008, 177:1164-1170.
14. Metcalfe J.Z., Cattamanchi A., McCulloch C.E., Lew J.D., Ha N.P., Graviss E.A. Test variability of the QuantiFERON-TB Gold In-Tube assay in clinical practice. Am J Respir Crit Care Med 2013, 187:206-211.
15. Ringshausen F.C., Nienhaus A., Schablon A., Schlosser S., Schultze-Werninghaus G., Rohde G. Predictors of persistently positive Mycobacterium tuberculosis-specific interferon-gamma responses in the serial testing of health care workers. BMC Infect Dis 2010, 10:220.
16. Dyrhol-Riise A.M., Gran G., Wentzel-Larsen T., Blomberg B., Haanshuus C.G., Morkve O. Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-Tube assay in outpatients from a tuberculosis low-endemic country. BMC Infect Dis 2010, 10:57.
17. Bartalesi F., Goletti D., Spinicci M., Cavallo A., Attala L., Mencarini J., et al. Serial QuantiFERON TB-Gold In-Tube testing during LTBI therapy in candidates for TNFi treatment. J Infect 2013, 66:346-356.
18. Pai M., Joshi R., Dogra S., Zwerling A.A., Gajalakshmi D., Goswami K., et al. T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int J Tuberc Lung Dis 2009, 13:84-92.
19. Vacher-Coponat H., Brunet C., Lyonnet L., Bonnet E., Loundou A., Sampol J., et al. Natural killer cell alterations correlate with loss of renal function and dialysis duration in uraemic patients. Nephrol Dial Transplant 2008, 23:1406-1414.
20. de Cal M., Cruz D.N., Corradi V., Nalesso F., Polanco N., Lentini P., et al. HLA-DR expression and apoptosis: a cross-sectional controlled study in hemodialysis and peritoneal dialysis patients. Blood Purif 2008, 26:249-254.
21. Shu C.C., Wang J.T., Lee C.H., Wang J.Y., Lee L.N., Yu C.J. Predicting results of mycobacterial culture on sputum smear reversion after anti-tuberculous treatment: a case control study. BMC Infect Dis 2010, 10:48.
22. Zwerling A.C.-L.J., Pietrangelo F., Behr M., Schwartzman K., Dendukuri N., Menzies D., et al. Conversions and reversions in health care workers in Montreal, Canada using QuantiFERON-TB-Gold In-Tube. Am J Respir Crit Care Med 2009, A1012.
23. Lin H.H., Ezzati M., Chang H.Y., Murray M. Association between tobacco smoking and active tuberculosis in Taiwan: prospective cohort study. Am J Respir Crit Care Med 2009, 180:475-480.
24. Rosner B.A. Estimation fro the binomial distribution. Fundam Biostat 2011, 181-188.
25. Adetifa I.M., Ota M.O., Jeffries D.J., Lugos M.D., Hammond A.S., Battersby N.J., et al. Interferon-gamma ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection: a clinical trial. Am J Respir Crit Care Med 2013, 187:439-445.
26. van Zyl-Smit R.N., Pai M., Peprah K., Meldau R., Kieck J., Juritz J., et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med 2009, 180:49-58.
27. Wickstrom G., Bendix T. The "Hawthorne effect" - what did the original Hawthorne studies actually show?. Scand J Work Environ Health 2000, 26:363-367.
28. Harada N., Higuchi K., Yoshiyama T., Kawabe Y., Fujita A., Sasaki Y., et al. Comparison of the sensitivity and specificity of two whole blood interferon-gamma assays for M. tuberculosis infection. J Infect 2008, 56:348-353.
29. Wang J.Y., Shu C.C., Lee C.H., Yu C.J., Lee L.N., Yang P.C. Interferon-gamma release assay and Rifampicin therapy for household contacts of tuberculosis. J Infect 2012, 64:291-298.
30. Chen D.Y., Shen G.H., Hsieh T.Y., Hsieh C.W., Lan J.L. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 2008, 59:800-806.
31. Fong K.S., Tomford J.W., Teixeira L., Fraser T.G., van Duin D., Yen-Lieberman B., et al. Challenges of interferon-gamma release assay conversions in serial testing of health-care workers in a TB control program. Chest 2012, 142:55-62.
32. Shu C.C., Wu H.D., Yu M.C., Wang J.T., Lee C.H., Wang H.C., et al. Use of high-dose inhaled corticosteroids is associated with pulmonary tuberculosis in patients with chronic obstructive pulmonary disease. Medicine (Baltimore) 2010, 89:53-61.
33. Baussano I., Nunn P., Williams B., Pivetta E., Bugiani M., Scano F. Tuberculosis among health care workers. Emerg Infect Dis 2011, 17:488-494.
34. Chang F.Y., Chou J.H., Chen Y.H., Yang S.Y., Liu D.P., Chen C.H., et al. Cdc annual report 2012 2012, Centers of Disease Control, Department of Health, Taipei, R.O.C. (Taiwan).
35. Wang J.Y., Liu C.H., Hu F.C., Chang H.C., Liu J.L., Chen J.M., et al. Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J Infect 2011, 62:448-455.